CRL
NYSE · Life Sciences Tools & Services
Charles River Laboratories
$337.52
+24.50 (+7.83%)
Financial Highlights (FY 2026)
Revenue
3.75B
Net Income
-134,934,956
Gross Margin
35.0%
Profit Margin
-3.6%
Rev Growth
+0.3%
D/E Ratio
0.68
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 35.0% | 35.0% | 66.6% | 66.6% |
| Operating Margin | 0.6% | 0.6% | 20.0% | 22.0% |
| Profit Margin | -3.6% | -3.4% | 15.4% | 18.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.75B | 3.74B | 1.98B | 1.66B |
| Gross Profit | 1.31B | 1.31B | 1.32B | 1.10B |
| Operating Income | 23.65M | 21.21M | 395.10M | 365.66M |
| Net Income | -134,934,956 | -121,042,021 | 304.29M | 307.56M |
| Gross Margin | 35.0% | 35.0% | 66.6% | 66.6% |
| Operating Margin | 0.6% | 0.6% | 20.0% | 22.0% |
| Profit Margin | -3.6% | -3.4% | 15.4% | 18.6% |
| Rev Growth | +0.3% | +0.3% | +16.2% | +9.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.15B | 3.15B | 2.06B | 1.87B |
| Total Equity | 4.67B | 4.67B | 3.63B | 3.31B |
| D/E Ratio | 0.68 | 0.68 | 0.57 | 0.56 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 190.92M | 180.78M | 664.62M | 536.40M |
| Free Cash Flow | — | — | 311.82M | 266.24M |